摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-氯苯基)-2-甲基-3-糠酸 | 111787-89-4

中文名称
5-(4-氯苯基)-2-甲基-3-糠酸
中文别名
5-(4-氯苯基)-2-甲基-3-呋喃羧酸;5-(4-氯苯基)-2-甲基-呋喃-3-羧酸
英文名称
2-methyl-5-(4-chlorophenyl)-furan-3-carboxylic acid
英文别名
5-(4-chlorophenyl)-2-methyl-3-furancarboxylic acid;5-(4-chlorophenyl)-2-methylfuran-3-carboxylic acid
5-(4-氯苯基)-2-甲基-3-糠酸化学式
CAS
111787-89-4
化学式
C12H9ClO3
mdl
MFCD00275560
分子量
236.655
InChiKey
HUQOLZUHGMRQFS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    229-232°C
  • 沸点:
    383.7±42.0 °C(Predicted)
  • 密度:
    1.327±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.083
  • 拓扑面积:
    50.4
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 安全说明:
    S22,S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2932190090
  • 危险品运输编号:
    UN 3261

SDS

SDS:00d9b77dbef9616486f7af81c128b712
查看
Name: 5-(4-Chlorophenyl)-2-methyl-3-furoic acid Material Safety Data Sheet
Synonym: None known
CAS: 111787-89-4
Section 1 - Chemical Product MSDS Name: 5-(4-Chlorophenyl)-2-methyl-3-furoic acid Material Safety Data Sheet
Synonym: None known
SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
111787-89-4 5-(4-Chlorophenyl)-2-methyl-3-furoic a 97+% unlisted
Hazard Symbols: C
Risk Phrases: 34
SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Causes burns. Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
No information found.
SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.
SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.
SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.
SECTION 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container. Corrosives area.
SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 111787-89-4: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Powder
Color: Brown
Odor: Without to slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 229 - 232 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H9ClO3
Molecular Weight: 236.66
SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported
SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 111787-89-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(4-Chlorophenyl)-2-methyl-3-furoic acid - Not listed by ACGIH, IARC, or NTP.
SECTION 12 - ECOLOGICAL INFORMATION
SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.
SECTION 14 - TRANSPORT INFORMATION IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III
SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust. S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 36/37/39 Wear suitable protective clothing, gloves and eye/face protection. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 111787-89-4: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 111787-89-4 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 111787-89-4 is not listed on the TSCA inventory. It is for research and development use only.
SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 3/23/2005 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors of P2X3
    申请人:Brotherton-Pleiss E. Christine
    公开号:US20070037974A1
    公开(公告)日:2007-02-15
    Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders: wherein R 1 is —C(═S)CH 3 , pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R 2a and R 2b are independently H, methyl, or ethyl; R 3 is H or methyl; Y is a bond, —(CR 4 R 5 ) n — or —CR 4 ═CR 5 —; wherein R 4 and R 5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R 6 , R 7 and R 8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R 6 and R 7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R 1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.
    式1的化合物是P2X3的调节剂,用于治疗疼痛和泌尿生殖、胃肠和呼吸系统疾病: 其中 R 1 为—C(═S)CH 3 ,吡啶基,嘧啶基,吡嗪基,噻唑基,呋喃基,呋喃甲酰基,乙酰基或氨基甲酰基;R 2a 和R 2b 独立地为H,甲基或乙基;R 3 为H或甲基;Y为键,—(CR 4 R 5 ) n —或—CR 4 ═CR 5 —;其中R 4 和R 5 各自独立地为H或甲基,n为1或2;X为N或CH;A为苯基,5-成员杂环基或6-成员杂环基;R 6 ,R 7 和R 8 各自独立地为H,卤素,低碳基,环烷基,烷基硫醚,烷基硫醚-低碳基,烷基磺酰基-低碳基,二(低碳基)氨基-低碳基,吗啉基-低碳基,4-甲基哌嗪基-甲基,三氟甲基,吡啶基,四唑基,噻吩基,苯基,联苯基或苄基(其中噻吩基,苯基和苄基被0-3个低碳基,卤素,磺酰胺基,三氟甲基,低烷氧基或低烷硫基取代)或R 6 和R 7 一起形成一个被0-3个取自由低碳基,低烷氧基,氧代基,卤素,噻吩基-低碳基,苯基,苄基(其中苯基和苄基被0-3个低碳基,卤素,磺酰胺基,三氟甲基,低烷氧基,低烷硫基,氨基-低碳基,烷基氨基-低碳基或二(低碳基)氨基-低碳基取代)的5-成员或6-成员碳环或杂环取代环;及其药学上可接受的盐;其中当R 1 为嘧啶-2-基时,X为N,Y为键,A为噁唑-5-基时,所述噁唑-5-基中位置4的碳原子在所述噁唑-5-基中位置2的碳原子被取代的苯基取代时不被丙基取代,且所述噁唑-5-基中位置4的碳原子在位置2被取代的苯基取代时不被苯基取代。
  • Substituted Cyclohexylmethyl Compounds
    申请人:OBERBOERSCH Stefan
    公开号:US20090286833A1
    公开(公告)日:2009-11-19
    Novel cyclohexylmethyl compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4 and R 5 , have the meanings given in the description. Pharmaceutical formulations containing these compounds, as well as a processes for preparing these compounds and related methods of treatment are also provided.
    新型环己基甲基化合物对应于式I,其中R1、R2、R3、R4和R5在描述中给出了它们的含义。还提供了含有这些化合物的药物配方,以及制备这些化合物的过程和相关治疗方法。
  • HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
    申请人:Uchida Hiroshi
    公开号:US20130079306A1
    公开(公告)日:2013-03-28
    A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.
    提供了一种新型杂环化合物或其盐,用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式(1)表示:其中A代表烷基、环烷基、芳基或杂环基,基团A可能有取代基;环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环,环B可能有取代基;环C代表芳香环,环C可能有取代基;L代表包含3至5个原子的主链的连接物,所述原子选自碳原子、氮原子、氧原子和硫原子组成的群,其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子,连接物L可能有取代基;n为0或1。
  • 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
    申请人:Wyeth
    公开号:US20030045560A1
    公开(公告)日:2003-03-06
    This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1 Wherein: Ar is phenyl, naphthyl, furanyl, benzofuranyl, indolyl, pyrazolyl, oxazolyl, fluorenyl, phenylcycloalkane where the cycloalkane can be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and Ar can be optionally substituted by 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, phenyl-(CH 2 ) 0-6 —, phenyl-(CH 2 ) 0-6 O—, C 3 -C 6 cycloalkyl, —(CH 2 )—C 3 -C 6 cycloalkyl, halogen, C 1 -C 3 perflouroalkyl and C 1 -C 3 perfluoroalkoxy where phenyl can be substituted with from 1 to 3 groups selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, phenyl, halogen, trifluoromethyl or trifluoromethoxy; R 1 is hydrogen, C 1 -C 6 alkyl or phenyl-(CH 2 ) 1-6 — where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 2 and R 3 are H, C 1 -C 6 alkyl, phenyl-(CH 2 ) 0-3 —, halo and C 1 -C 3 perfluoroalkyl where phenyl can be substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, trifluoromethyl or trifluoromethoxy; R 4 is —CHR 5 CO 2 H or —CH 2 -tetrazole where R 5 is H or benzyl; and n=0 or 1; or a pharmaceutically acceptable salt or ester form thereof.
    这项发明提供了新颖的化合物、药物组合物和治疗哺乳动物血栓性疾病的方法,这些化合物具有以下结构式:1其中:Ar为苯基、萘基、呋喃基、苯并呋喃基、吲哚基、吡唑基、噁唑基、芴基、苯基环烷烃,其中环烷烃可以是环丙基、环丁基、环戊基或环己基,Ar可以选择性地被1至3个来自C1-C6烷基、C1-C6烷氧基、羟基、苯基-(CH2)0-6—、苯基-(CH2)0-6O—、C3-C6环烷基、—(CH2)—C3-C6环烷基、卤素、C1-C3全氟烷基和C1-C3全氟烷氧基的基团取代;R1为氢、C1-C6烷基或苯基-(CH2)1-6—,其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代;R2和R3为H、C1-C6烷基、苯基-(CH2)0-3—、卤素和C1-C3全氟烷基,其中苯基可以被C1-C6烷基、C1-C6烷氧基、卤素、三氟甲基或三氟甲氧基取代;R4为—CHR5CO2H或—CH2-四唑基,其中R5为H或苄基;n=0或1;或其药用可接受的盐或酯形式。
  • [DE] HETEROARYLSUBSTITUIERTE CYCLOHEXYL-1,4-DIAMIN-DERIVATE<br/>[EN] HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES<br/>[FR] DERIVES DE CYCLOHEXYLE-1,4-DIAMINE SUBSTITUES PAR HETEROARYLE
    申请人:GRUENENTHAL GMBH
    公开号:WO2005110971A1
    公开(公告)日:2005-11-24
    Die vorliegende Erfindung betrifft substituierte Cyclohexyl-1,4-diamin-Derivate, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung von substituierten Cyclohexyl-1,4-diamin-Derivaten zur Herstellung von Arzneimitteln.
    这项发明涉及取代的环己基-1,4-二胺衍生物、其制备方法、含有这些化合物的药物以及利用取代的环己基-1,4-二胺衍生物制备药物的用途。
查看更多

同类化合物

除草醚 醋糠硫胺 醋呋三嗪 酪氨酰-甘氨酰-色氨酰-蛋氨酰-门冬氨酰-苯基丙氨酰-甘氨酸 糠酸(呋喃甲酸) 糠酸異戊酯 糠酸烯丙酯 碘化溴刚 硫代糠酸甲酯 硝基呋喃杂质 硝呋隆 硝呋醛肟标准品 硝呋美隆 硝呋维啶 硝呋立宗 硝呋甲醚 硝呋烯腙盐酸盐 硝呋烯腙 硝呋替莫 硝呋拉定 硝呋太尔杂质B 硝呋噻唑 硝呋乙宗 盐酸呋喃它酮 盐酸呋喃他酮 甲基7-[5-乙酰氨基-4-[(2-溴-4,6-二硝基苯基)偶氮]-2-甲氧苯基]-3-羰基-2,4,10-三氧杂-7-氮杂十一烷-11-酸酯 甲基5-溴-3-甲基-2-糠酸酯 甲基5-乙酰氨基-2-糠酸酯 甲基5-{[(氯乙酰基)氨基]甲基}-2-糠酸酯 甲基5-(甲氧基甲基)-2-甲基呋喃-3-羧酸酯 甲基5-(溴甲基)-4-(氯甲基)-2-糠酸酯 甲基5-(乙氧基甲基)-2-甲基-3-糠酸酯 甲基5-({[5-(三氟甲基)-2-吡啶基]硫代}甲基)-2-糠酸 甲基5-(4-甲酰基苯基)-2-糠酸酯 甲基5-(3-甲酰基苯基)-2-糠酸酯 甲基4-甲基-3-糠酸酯 甲基4-溴-5-甲基-2-糠酸酯 甲基4-乙酰基-5-甲基-2-糠酸酯 甲基4,6-二氯-3-(二乙基氨基)呋喃并[3,4-c]吡啶-1-羧酸酯 甲基3-羟基呋喃并[3,2-b]吡啶-2-羧酸酯 甲基3-甲酰基-2-糠酸酯 甲基3-氨基呋喃并[2,3-b]吡啶-2-羧酸酯 甲基3-氨基-5-(2-甲基-2-丙基)-2-糠酸酯 甲基3-乙基-4-苯基-2-糠酸酯 甲基3-(叔丁氧基羰基)呋喃-2-羧酸甲酯 甲基2-甲氧基-5-苯基-3-糠酸酯 甲基2-乙基-3-糠酸酯 甲基(2Z)-2-呋喃-2-基-3-(5-硝基呋喃-2-基)丙-2-烯酸酯 甲基(2E)-3-[5-(氯甲酰基)-2-呋喃基]丙烯酸酯 环己基呋喃-2-羧酸酯